EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

CICLESONIDE IN ADDITION TO TIOTROPIUM AND FORMOTEROL IN MILD TO MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RANDOMISED, DOUBLE BLIND STUDY

Divyesh R. Mandavia, V. Ghori, Ajay Savaliya, Jigna Dave, Narenda Paliwal and C. B. Tripathi* 

ABSTRACT

Introduction: Chronic obstructive pulmonary disease (COPD) is one of the most common lung disease characterised by chronic inflammation of bronchioles. There are very few evidences on use of pharmacotherapy, especially with inhaled corticosteroid, in COPD with FEV1 > 60%. Objective: This pilot study was designed to evaluate efficacy and safety of formoterol, tiotropium dual (FT/D) and formoterol, tiotropium, ciclesonide triple (FTC/T) combinations in the cases of COPD with FEV1 > 50%. Methods: This was 12 weeks, randomized, double-blind, parallel group study. COPD patients, 35 – 70 years old, with history of smoking ≥ 10 pack years, FEV1 > 50% of predicted and FEV1/FVC < 0.7 were included in this study. Eligible patients were randomly allocated to FT/D or FTC/T metered dose inhaler treatment groups in double blind manner. The pulmonary function test, six minute walk test (6 MWT) and adverse event profile were evaluated at every 4 weeks. Results: Forty-six (23 per group) subjects completed the study and analysed on intent to treat basis. There was significant improvement in FEV1 and 6 MWD within the group at 12 weeks in both the groups when compared to baseline, while there was not any significant difference between the groups. The FVC was significantly improved in FTC/T treatment group at 12 weeks compared to baseline. There was no significant difference in adverse drug reaction profiles between the groups. Conclusion: The present study suggests that addition of ciclesonide to formoterol and tiotropium does not improve lung function or exercise endurance more than bronchodilators alone. (CTRI/2011/091/000182).

Keywords: Ciclesonide, Tiotropium bromide, Formoterol, Mild to moderate COPD, Pulmonary function test, Six minute walk test.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 December 2021 Issue has been Published, Kindly check it on http://www.ejpmr.com/home/current_issues

  • EJPMR: DECEMBER ISSUE PUBLISHED

    DECEMBER Issue has been successfully launched on 1 December 2021.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI )